1-3 of 3
Michael Kuziora
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Ph2 Study of MEDI0680 in Combination With Durvalumab vs. Nivolumab Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Martin H. Voss, Arun A. Azad, Aaron R. Hansen, Jhanelle E. Gray, Sarah J. Welsh, Xuyang Song, Michael Kuziora, Lina Meinecke, Jorge Blando, Ikbel Achour, Yi Wang, Farzana Walcott, Sjoukje F. Oosting
Journal: Clinical Cancer Research
Clin Cancer Res clincanres.4115.2021.
DOI: https://doi.org/10.1158/1078-0432.CCR-21-4115
Published: 04 May 2022
View article
PDF
Includes: Supplementary data
Journal Articles

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Han Si, Michael Kuziora, Katie J. Quinn, Elena Helman, Jiabu Ye, Feng Liu, Urban Scheuring, Solange Peters, Naiyer A. Rizvi, Philip Z. Brohawn, Koustubh Ranade, Brandon W. Higgs, Kimberly C. Banks, Vikram K. Chand, Rajiv Raja
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (6): 1631–1640.
DOI: https://doi.org/10.1158/1078-0432.CCR-20-3771
Published: 15 March 2021
View article
PDF
Includes: Supplementary data
Journal Articles

Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab

Rajiv Raja, Michael Kuziora, Philip Z. Brohawn, Brandon W. Higgs, Ashok Gupta, Phillip A. Dennis, Koustubh Ranade
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (24): 6212–6222.
DOI: https://doi.org/10.1158/1078-0432.CCR-18-0386
Published: 13 December 2018
View article
PDF
Includes: Supplementary data